Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M245,914Revenue $M50,370Net Margin (%)17.7Altman Z-Score3.8
Enterprise Value $M246,420EPS $1.4Operating Margin %27.0Piotroski F-Score5
P/E(ttm)25.4Beneish M-Score-2.8Pre-tax Margin (%)24.0Higher ROA y-yN
Price/Book13.810-y EBITDA Growth Rate %4.7Quick Ratio1.0Cash flow > EarningsY
Price/Sales4.85-y EBITDA Growth Rate %3.8Current Ratio1.4Lower Leverage y-yN
Price/Free Cash Flow18.8y-y EBITDA Growth Rate %-10.2ROA % (ttm)13.0Higher Current Ratio y-yN
Dividend Yield %2.8PEG6.6ROE % (ttm)49.6Less Shares Outstanding y-yY
Payout Ratio %74.0Shares Outstanding M6,810ROIC % (ttm)32.9Gross Margin Increase y-yN

Gurus Latest Trades with RHHBY

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
RHHBYKen Fisher 2015-06-30 Add0.8%$34.38 - $38.46
($36.09)
$ 36.110%Add 409.71%14,211,412
RHHBYKen Fisher 2015-03-31 Reduce$32.1 - $36.505
($34.06)
$ 36.116%Reduce 1.24%2,788,126
RHHBYKen Fisher 2014-12-31 Add0.07%$34.16 - $37.92
($36.33)
$ 36.11-1%Add 49.26%2,823,025
RHHBYKen Fisher 2014-06-30 Reduce-0.07%$35.42 - $38.07
($36.82)
$ 36.11-2%Reduce 49.71%1,813,443
RHHBYKen Fisher 2014-03-31 Add0.07%$18.14 - $38.17
($29.75)
$ 36.1121%Add 99.00%3,606,140
RHHBYKen Fisher 2013-12-31 Reduce$31.96 - $35.24
($34.15)
$ 36.116%Reduce 0.26%1,812,112
RHHBYKen Fisher 2013-09-30 Add$30.655 - $33.765
($31.86)
$ 36.1113%Add 0.28%1,816,868
RHHBYTweedy Browne 2013-06-30 Sold Out $28.92 - $32.98
($30.91)
$ 36.1117%Sold Out0
RHHBYKen Fisher 2013-06-30 Add$28.92 - $32.98
($30.91)
$ 36.1117%Add 0.90%1,811,804
RHHBYKen Fisher 2013-03-31 Add0.12%$25.615 - $29.3
($27.78)
$ 36.1130%Add 634.57%1,795,722
RHHBYTweedy Browne 2012-12-31 Reduce$23.08 - $25.68
($24.53)
$ 36.1147%Reduce 3.04%120,548
RHHBYKen Fisher 2012-12-31 Reduce$23.08 - $25.68
($24.53)
$ 36.1147%Reduce 14.81%244,460
RHHBYTweedy Browne 2012-09-30 Reduce-0.03%$20.985 - $24.07
($22.5)
$ 36.1160%Reduce 24.31%124,328
RHHBYKen Fisher 2012-09-30 Reduce$20.985 - $24.07
($22.5)
$ 36.1160%Reduce 7.27%286,946
RHHBYVanguard Health Care Fund 2012-06-30 Add2.96%$19.43 - $23.14
($21.18)
$ 36.1170%Add 543.36%8,547,954
RHHBYKen Fisher 2012-06-30 Reduce-0.01%$19.43 - $23.14
($21.18)
$ 36.1170%Reduce 24.26%309,426
RHHBYKen Fisher 2012-03-31 Reduce-1.27%$20.885 - $22.5
($21.78)
$ 36.1166%Reduce 98.02%408,552
RHHBYTweedy Browne 2012-03-31 Reduce-0.04%$20.885 - $22.5
($21.78)
$ 36.1166%Reduce 22.19%164,260
RHHBYKen Fisher 2011-12-31 Reduce-0.26%$18.31 - $21.33
($20.11)
$ 36.1180%Reduce 15.75%20,679,972
RHHBYTweedy Browne 2011-12-31 Reduce$18.31 - $21.33
($20.11)
$ 36.1180%Reduce 0.53%211,110
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

RHHBY is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


RHHBY: Insider Buys/Sells

Click Here for All Insider Trades.

No Insider Trades Found!

Quarterly/Annual Reports about RHHBY:

    News about RHHBY:

    Articles On GuruFocus.com
    Ken Fisher's most weighted buys in Q2 2015 Jul 28 2015 
    UnitedHealth Group Reports Strong Second Quarter Earnings Results Jul 21 2015 
    It’s Not Too Late To Buy Gilead Sciences Jul 17 2015 
    Baxter Takes The Acquisition Route To Grow In The Oncology Segment May 14 2015 
    Roche’s Oncology Drugs Drive Its Revenue Northwards In Q1 Apr 24 2015 
    Top Weighted Stocks in Tweedy Browne Global Value Fund's Portfolio Apr 22 2015 
    What Are The Intrinsic Factors Contributing To Pfizer’s Stock Movement? Mar 27 2015 
    AbbVie To Acquire Biopharmaceutical Firm Pharmacyclics Mar 06 2015 
    Small Cap Biotech Growth Stocks For 2015 Mar 05 2015 
    Can These Three BioTech Companies Make It Big? Feb 20 2015 

    More From Other Websites
    Sea Turtle Scientist Hunts for China’s First Blockbuster Jul 30 2015
    3:23 am Roche Hldg submits FDA filing for companion diagnostic for non-small cell lung cancer drug... Jul 30 2015
    Roche submits filing to FDA for companion diagnostic for non-small cell lung cancer drug therapy Jul 30 2015
    Roche introduces LabLeaders educational initiative to help redefine the value of the laboratory at... Jul 28 2015
    Roche Earnings Down Y/Y, Oncology/Immunology Drive Sales - Analyst Blog Jul 24 2015
    Multiple Studies Show Superiority of Critical Diagnostics’ ST2 over BNP, NT-proBNP and Other Heart... Jul 24 2015
    Avalanche Biotech CEO Chalberg Resigns After Disappointing Trial Jul 23 2015
    Roche readies new drugs in two-year window before copycats hit Jul 23 2015
    AC Immune to Decide This Year on IPO or Sale as Roche Tests Drug Jul 23 2015
    Roche Performance Strong on Drug Pipeline: Schwan (Video) Jul 23 2015
    Roche sees 1st-half profit drop on franc strength; sales up Jul 23 2015
    Roche sees 1st-half profit drop on franc strength; sales up Jul 23 2015
    European Factors-Futures higher after C.Suisse results beat Jul 23 2015
    Roche Battered by Strong Swiss Franc Jul 23 2015
    New products will drive growth: Roche CEO Jul 23 2015
    Roche Profit Little Changed as Swiss Franc Masks New Drug Growth Jul 23 2015
    Isis Pharmaceuticals Begins Huntington's Disease Study - Analyst Blog Jul 22 2015
    Hedge Funds Love These 5 Big Stocks -- Should You? Jul 22 2015
    Roche expands HIV Global Access Program to include infants in resource limited settings Jul 19 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    Steve.dunfield@google
    ReplySteve.dunfield@google - 1 year ago
    Adjust for split?
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK